Abstract
Aumolertinib has shown efficacy in EGFR-mutant NSCLC patients with brain metastases in the phase III AENEAS study. ACHIEVE (NCT04808752) is an ongoing multicenter, open-label, single-arm study evaluating high-dose (165mg) third-generation EGFR-TKI aumolertinib (formerly almonertinib; HS-10296) as first-line therapy in EGFR-mutant NSCLC patients with brain metastases. Here we report primary data from ACHIEVE.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
